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Synthesis of Calcineurin-Resistant Derivatives
of FK506 and Selection of Compensatory Receptors
(FKBP12) [2, 8, 11], and their use has become wide-
spread in biological research. Early work in the prepara-
tion of homodimerizers focused on semisynthetic di-
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based efforts to engineer fully synthetic FKBP12 ligandsHarvard University
12 Oxford Street have met with much success [7, 14]. In general, using
synthetic small molecules makes more tractable theCambridge, Massachusetts 02138
4 Institute of Chemistry and Cell Biology problem of engineering small molecule-protein combi-
nations that do not interfere with the cellular functionsHarvard Medical School
250 Longwood Avenue of endogenous FKBP12 [15–17]. In particular, -keto-
pipecolyl-amide derivatives [7] that selectively bind toBoston, Massachusetts 02115
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[9, 14]. Such FKBP12 “bump-hole” systems are ex-
tremely valuable models for molecular design and theSummary
general study of small molecule-protein interactions
[18]. Indeed, this approach, originally developed in theWe used olefin metathesis to synthesize C40 deriva-
context of exploring protein phosphatase function [19,tives of FK506 and measured their ability, when com-
20], has recently been extended to the study of proteinplexed to FKBP12, to inhibit calcineurin’s phosphatase
kinases [21, 22].activity. We identified modular dimerization domains
Dimerizers are also important tools in cell signaling(CABs) containing segments of the calcineurin A and
research, particularly in cases where proximity effectsB polypeptides. These CABs respond to FK506 both
are thought to dominate the regulatory logic of a givenwhen overexpressed in mammalian cells and in yeast
protein. In general, dimerization domains (e.g., FKBP12)or mammalian three-hybrid assays. Using chemical
are fused to a protein of interest to produce a conditionalgenetic selection, we identified compensatory mutant
allele [2, 23], making some protein function dependentCABs that respond to a calcineurin-resistant FK506
on the presence of a dimerizer. Used in this manner,derivative at concentrations well below the response
dimerizer systems form a branch of reverse chemicalthreshold for CABs containing only wild-type calcineurin
genetics [24] (targeted modulation of protein functionsequence. These reagents provide a small molecule-
followed by a broad search for the resulting phenotype)protein combination orthogonal to existing dimerizer
and have been used directly to control membrane re-systems and may be used with existing systems to
ceptors [25], protein kinases [26, 27], death domainsincrease the complexity of induced-proximity experi-
[3, 28], and transcription factors [29]. For a completements. This new use of the “bump-hole” strategy pro-
list of dimerizer references, see http://www.ariad.com/tects target cells from complications arising from the
regulationkits/reg_ref1.html.inhibition of endogenous calcineurin.
FK506 [2, 11], -keto-pipecolyl-amides [8, 9], cyclo-
sporin [3], and coumermycin [5] have been converted
Introduction into homodimerizers, which are well-suited for circum-
stances in which the homodimerization of a single pro-
Collectively termed dimerizers or chemical inducers of tein is sufficient to initiate a biological response. In a
dimerization (CIDs) [1], small molecules that induce simple instance of a homodimerizer system, FK1012
proximal relationships (“dimerization”) between pro- was used to homodimerize the Bcl family member Bax
teins include both semi-synthetic derivatives of natural [28]. In this case, fusion of Bax to FKBP12 yielded a
agents [2–6] and small molecules prepared by total or- single construct system that responds to FK1012 by
ganic synthesis [7–9]. The rationale for the use of dimer- forming a tripartite signaling complex (Figure 1A). In a
izer systems to control signal transduction comes from slightly more complicated model, exemplified by the
the fact that they exploit a known regulatory bias of T cell receptor  chain [2, 30], tandem FKBP12 modules
certain families of proteins. Namely, this bias is that were appended to the receptor kinase domain. In this
protein function is controlled by regulated protein local- case, addition of the dimerizer promotes aggregation of
ization in vivo [1, 10]. The most widely used dimerization the fusion protein (Figure 1B) and mimics the situation
systems are based on natural and synthetic small mole- of antigen presentation and receptor capping in vivo.
cules that bind to the 12 kDa FK506 binding protein Homodimerizers have also been used in heterologous
systems, in which two different proteins or domains are
each fused separately to FKBP12 and then induced to5 Correspondence: sls@slsiris.harvard.edu
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Figure 1. Conceptual Uses of Dimerizers to
Induce Protein Proximity
Schematic representations include CIDs (yel-
low), dimerization domains (blue), effector
domains (red), and endogenous signaling
proteins (purple).
(A) Homodimerization for which a single-con-
struct system consisting of an effector do-
main fused to a single dimerization domain
was used. The panel illustrates unwanted in-
teractions with endogenous dimerization do-
mains (e.g., FKBP12).
(B) Oligomerization for which a single-con-
struct system consisting of an effector do-
main fused to multiple dimerization domains
was used. The panel llustrates unwanted in-
teractions with endogenous dimerization do-
mains.
(C) Dimerization of heterologous constructs
containing the same dimerization domain, but
different effector domains. The panel illus-
trates the formation of additional undesired
complexes between engineered proteins.
(D) Heterodimerization of heterologous constructs containing different dimerization domains and different effector domains. The panel illustrates
unwanted interaction with a CID-sensitive endogenous signaling protein (e.g., FRAP or calcineurin).
(E) Heterodimerization of heterologous constructs. A “bump-hole” strategy was used to protect endogenous signaling proteins.
(F) Formation of a multicomponent complex from two hemi-orthogonal heterodimerizers (e.g., rapamycin and FK506).
associate in a cellular context [2, 11]. An obvious prob- one [35]. Preparation of the newly engineered dimerizer
system proceeded in three stages: (1) synthesis andlem with this approach is that it allows the formation of
three different protein complexes (Figure 1C), excluding purification of calcineurin-resistant derivatives of FK506,
(2) identification of a modular receptor for FKBP12-those containing endogenous FKBP12 (in the case of
non-“bump-hole” systems) and higher-order complexes FK506 based on calcineurin protein sequence, and (3)
chemical genetic selection of mutant proteins by theresulting from the use of tandem FKBP12 modules, as
described above. For this reason, among others, hetero- use of calcineurin-resistant derivatives of FK506 in a
yeast three-hybrid assay. Because this new dimerizerdimerizers have been developed to effect the specific for-
mation of the heterodimeric complex of interest [4, 6]. system is hemi-orthogonal to that based on rapamycin
(i.e., both compounds bind FKBP12), we envision thatEarly efforts to prepare heterodimerizers included the
synthesis of FK-CsA, a semi-synthetic heterodimer of its future use in tandem with the rapamycin-based sys-
tem will allow the specific and ordered assembly ofFK506 and cyclosporin A (CsA) [4]. More recently, hetero-
dimerizer work has focused on dexamethasone-meth- multicomponent protein complexes ([36, 37]; Figure 1F).
otrexate [4, 6] and on the macrolide natural product,
rapamycin. A natural heterodimerizer, rapamycin medi- Results
ates the interaction of FKBP12 with the PIK-related ki-
nase FRAP [31]. Conveniently, a small, stable domain Preparation of Calcineurin-Resistant FK506
Derivatives by Olefin Metathesisof FRAP (residues 2025-2113), termed the FKBP12-
rapamycin binding (FRB) domain [32], is competent to The major drawback of using FK506 (1) as a dimerizer
to control cellular signal transduction is its natural bio-bind the FKBP12-rapamycin complex. However, the ki-
nase activity of endogenous FRAP is potently modulated logical activity. Calcineurin is a heterodimeric (A/B), cal-
cium-dependent protein phosphatase necessary for theat relatively low concentrations of rapamycin [33], lim-
iting the use of rapamycin itself as a dimerizer (Figure propagation of cytokine receptor signals in lymphocytes
[38] and for synaptic vesicle recycling [39] and synaptic1D). This limitation was circumvented by appending ste-
rically bulky groups to rapamycin at the interface of its depotentiation in neurons [40]. The FKBP12-FK506 com-
plex binds to calcineurin A/B and inhibits its phospha-interaction with FRB. Specifically, C20-(S)-methallyl-
rapamycin was shown to select for a mutant allele tase activity; the three-dimensional structure of this in-
hibitory quaternary complex has been determined at(termed FRB*; K2095P/T2098L/W2101F) over the “wild-
type” FRB domain [34]. Thus, a FRAP-resistant rapa- atomic resolution [41]. The terminal olefin (C39-C40) of
FK506 protrudes into an interface between the cal-mycin derivative, used in concert with both FKBP12 and
FRB* fusion proteins, can elicit specific heterodimeriza- cineurin B binding helix (BBH) [41] of calcineurin A (CnA)
and the third EF hand (a structural motif common to Ca2tion of two proteins (Figure 1E) without the side effect
of endogenous FRAP inhibition. binding proteins [42]) of calcineurin B (CnB), making
this an attractive moiety for derivatization (Figure 2A).Here we report the engineering of a novel heterodi-
merizer system based on FK506. Like rapamycin, FK506 Previous work to prepare FK1012s by olefin metathesis
[11] revealed that trace amounts of C40-phenyl-FK506is a natural dimerizer; it mediates the interaction of
FKBP12 with the calcineurin A/B heterodimer [35]. As (3) are produced as a by-product of the metathesis reac-
tion (Figure 2B). This product is expected because ruthe-with FRAP [33], calcineurin activity is inhibited by the
complex between FK506 and its immunophilin chaper- nium catalyst 2 is initially charged with benzylidene [43];
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Figure 2. Derivatization of FK506 by Olefin Metathesis
(A) Close-up, based on crystallographic coordinates (Protein Databank: 1TCO), of the binding interface of FKBP12 (magenta), FK506 (white),
CnA (green), and CnB (blue) [41]. The terminal olefin (C39-C40) of FK506 is shown in space-filling representation to illustrate its protrusion
into the binding interface.
(B) Synthetic scheme for the olefin metathesis reaction used to prepare C40-phenyl-FK506 (3; C40-Ph) and C40-p-phenoxyphenyl-FK506 (4;
C40-PhOPh).
(C) Additional olefin-containing compounds used to prepare C40--naphthyl-FK506 (C40-Nap), C40-m-fluorophenyl-FK506 (C40-FPh), C40-
p-iodophenyl-FK506 (C40-IPh), C40-trimethylsilane (C40-TMS), by the same method. All compounds were tested against endogenous cal-
cineurin (see Figure 3), after which only 3 and 4 were chosen for further study.
thus, the first catalytic cycle effectively results in the phorylation by calcineurin [44]. Inhibition of calcineurin
by FKBP12-FK506 prevents translocation of and tran-metathesis of styrene to FK506. We reasoned that the
proportion of 3 to FK1012 could be increased by includ- scriptional activation by NFAT. We transiently transfected
Jurkat human lymphoma cells with a plasmid (NRE-AP)ing additional styrene in the metathesis reaction, which
indeed turned out to be the case. Using a similar strat- harboring a secreted alkaline phosphatase (AP) reporter
gene downstream of twelve copies of an NFAT responseegy, we prepared C40-p-phenoxyphenyl-FK506 (4), and
a series of additional C40-“bump” derivatives of FK506 element (NRE) [45]. In transfected cells, the combination
of phorbol ester (PMA; phorbol-12-myristate-13-acetate)by cross-metathesis of the appropriate olefin-containing
starting material (Figure 2C). and ionomycin (Io) potently activates production of AP,
as judged by incubation of supernatants with a fluoro-The potency of 1 requires that any preparation of
a calcineurin-resistant derivative be completely free of genic substrate (MUP; 4-methylumbelliferylphosphate)
[4, 34, 46]. We exposed transfected cells to varying con-unreacted 1. Thus, reaction optimization focused on the
purity, rather than the yield, of C40 adducts. Because centrations of either 1 or one of the C40 derivatives after
stimulation with PMA/Io. The results of this experimentthe efficiency of metatheses involving 1 is relatively poor
[11], we used iterative rounds of separation by forward- (Figure 3) suggest that each derivative is less effective
at inhibiting calcineurin activity than is 1, as judged byphase (chloroform; CHCl3) recycling HPLC to effect puri-
fication. In this method, eluent from the HPLC column the observed shifts in effective concentration for half-
maximal effect (EC50) on AP production. This result couldis either reinjected onto the HPLC column or diverted
to a fraction collector under operator control. Reinjec- be due to effects other than steric interference by C40
substituents; differences in solubility, cell permeability,tion of eluate results in greater separation of peaks with
each cycle of the instrument. Separation can be further or ability to bind FKBP12 could account for this observa-
tion. To control for these possibilities, we performed aaugmented by “peak-shaving,” in which overlapping
shoulders from adjacent peaks are shunted to a waste cytoblot assay [47] in which 1, 3, or 4 was asked to
suppress the ability of rapamycin to inhibit cell divisionfraction. We monitored the purification process in real-
time by UV chart recording (254 nm). For both 3 and 4, by competing for binding to FKBP12 [48]. As both 3 and
4 (like 1) were able to suppress the effects of rapamycinwe determined the identity and purity of isolated product
peaks by both FAB-MS and 1 H-NMR. For other deriva- in this context (Brent R. Stockwell, P.A.C., and S.L.S.,
unpublished data), we are confident that both 3 and 4tives, we isolated 1 mg of each compound, which we
analyzed only for purity by FAB-MS (see Experimental are soluble, cell-permeable, and able to bind FKBP12.
Procedures), but which was nonetheless sufficient for
preliminary biological assays. Calcineurin Fusion Proteins and Dose-Dependent
Transcriptional ActivationTo test the ability of C40 metathesis adducts to inhibit
calcineurin function, we used a reporter gene assay that Active calcineurin phosphatase is composed of two
polypeptides (CnA and CnB) [49], each of which con-responds to 1 in a dose-dependent manner. The nuclear
factor of activated T cells (NFAT) is a transcription factor tacts FKBP12-FK506 in the crystal structure of the qua-
ternary complex (Figure 4A) [41]. To facilitate the use ofwhose nuclear localization is dependent on dephos-
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Figure 3. Effect of C40 Derivatization on Endogenous Calcineurin
Jurkat cells were transfected with NRE-AP reporter (50 ng/106 cells), stimulated with PMA/Io, and treated with serial dilutions of either FK506
(1) or the indicated C40 derivative. Abbreviations for CIDs are provided in the legend for Figure 2. Data are plotted as the average of either
five [FK506 (1), C40-Ph (3), C40-PhOPh (4), C40-Nap] or three [C40-FPh, C40-IPh, C40-TMS] independent experiments, and error bars (where
present) indicate the standard deviation of the mean.
calcineurin-derived modules for dimerizer research, we cineurin of a stimulus necessary to activate NRE-AP. In
this context, fCAB stimulates AP production in roughsought to prepare stable fusion proteins that were both
competent to bind FKBP12-FK506 and expressed as a proportion to transfected DNA concentration, and this
activation is sensitive both to 1 (Figure 5B) and 3 (Figuresingle polypeptide chain. The success of this approach
owes to the fact that the C terminus of truncated CnA 5C). Thus, the 65 kDa fCAB protein (Figure 5D) retains
calcineurin phosphatase activity and, more importantly,(residues 12–394) is close in space to the N terminus
of CnB [41]. Guided by this observation, we prepared is sensitive to inhibition by FK506. Moreover, the EC50
relationship between 1 and 3, established with endoge-constructs encoding two single-chain fusion proteins,
termed CABs for calcineurin A/B fusion proteins (Figure nous calcineurin, is preserved in these experiments,
suggesting that the C40 substituent of 3 is indeed re-4B). One construct includes both the phosphatase do-
main and BBH region [41] (residues 12–394) of CnA and sponsible for reduced interaction with fCAB in a cellular
context.is thus termed a functional CAB (fCAB; Figure 4C). A
shorter construct consists of only the BBH region [41] Because mCAB lacks phosphatase activity, we re-
quired another test to validate the ability of mCAB toof CnA (residues 340–394) fused to CnB; this construct
encodes a relatively small polypeptide (230 amino acids) interact in vivo with FKBP12-FK506. Following the lead
of previous work on rapamycin [34, 52], we used a mam-amenable for use as a modular CAB domain (mCAB;
Figure 4D). malian three-hybrid system [34, 52, 53] to study the
interaction of mCAB with FKBP12-FK506. We fusedTo test the ablility of fCAB to interact with FKBP12-
FK506 in vivo, we exposed stimulated (PMA/Io) Jurkat mCAB to the transcriptional activation domain (AD) of
the p65 subunit of human NF-B (residues 361–551) [52].cells cotransfected with NRE-AP and fCAB to varying
concentrations of 1. Not surprisingly, overexpression of The three-hybrid assay involves the recruitment of this
mCAB-AD protein to DNA decorated with FKBP12 (Fig-fCAB (which contains the CnA phosphatase domain)
completely suppressed the ability of 1 to inhibit AP pro- ure 6A). We chose as the reporter a construct containing
the Gal4 response element (GRE) fused to AP (GRE-AP).duction (Figure 5A). Because fCAB lacks both the cal-
modulin binding domain and the autoinhibitory domain For the bait, we chose a fusion of the Gal4 DNA binding
domain (BD) to three tandem copies of FKBP12 (BD-F3)(AID) [49, 50] of CnA, it is reasonable to expect that this
construct would act as a dominant positive allele in the [4, 34]. We cotransfected cells with all three constructs
and exposed them to varying concentrations of 1, 3, orAP reporter assay. Specifically, fCAB exhibits deregu-
lated phosphatase activity that, unlike endogenous cal- 4. For both derivatives, we observed a dose-dependent
increase in AP production, though with EC50 valuescineurin [49, 51], is independent of intracellular calcium
concentration. Experimentally, this allowed us to distin- higher than that of 1 (Figure 6B). Once again, these
results suggest a reduced ability of 3 or 4 to interactguish reporter production due to transfected fCAB from
that due to endogenous calcineurin. By omitting iono- with mCAB. Interestingly, mCAB-AD expression levels
increase with increasing concentration of DNA, whereasmycin from the assay, we deprived endogenous cal-
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Figure 4. Preparation of Calcineurin A/B Fusion Proteins (CABs)
Representations of the FKBP12-FK506-calcineurin A/B complex are based on the same crystallographic coordinates and follow the same
color scheme as in Figure 2.
(A) The C-terminal crystallographically resolved residue (Cys372) of CnA and the N-terminal residue (Gly2) of CnB are shown in space-filling
representation to illustrate their proximity in space; 24 residues separate these positions in the single-chain CAB proteins.
(B) Schematic representations of the exact coding sequences of both functional CAB (fCAB) and modular CAB (mCAB) fusion proteins. In
this study, we used human CnA, which differs from bovine CnA protein at only one residue (human, Ser59; bovine, Thr59) in the region of
interest. Human and bovine CnB are identical at the amino acid level. Restriction sites within the open-reading frames encode the following
amino acids (single-letter codes): XhoI (LE), SalI/XhoI fusion (VE), SalI (VD), and SpeI (TS).
(C) Crystallographically resolved residues present in the fCAB fusion protein.
(D) Crystallographically resolved residues present in the mCAB fusion protein.
AP activity decreases (Figure 6C), which probably re- CIDs resulted in the highest signal (Figure 6F). Although
more extensive tests of such double dimerizer systemsflects competition for cellular resources with the co-
transfected reporter and bait constructs. Finally, we are warranted, we feel that these results are sufficient
to demonstrate this aspect of the mCAB system.confirmed the physical association of mCAB with
FKBP12-FK506 by coimmunoprecipitation (Figure 6D) of
an FK506-dependent complex from cells cotransfected
with mCAB-AD and a construct encoding epitope- Identification and Validation of Compensatory
Mutants of mCABtagged FKBP12 (Figure 6D).
To compare the mCAB dimerization system with a pre- Much recent work in the redesign of small molecule-
protein interfaces, particularly work involving FKBP12viously developed heterodimerizer system based on the
FRB* domain [34], we directly compared mCAB-AD with and its ligands, has used a protein structure-based ap-
proach [7, 9, 14, 18, 54]. In contrast, we sought to extendFRB*-AD in parallel three-hybrid experiments. Jurkat cells
were cotransfected with reporter, bait, and either the power of genetics to protein discovery by using a
yeast three-hybrid selection strategy (Figure 7A) [53, 55,mCAB-AD or FRB*-AD. In these experiments, cells were
exposed to either rapamycin or FK506 at similar concen- 56]. This system is analogous to the mammalian three-
hybrid assay described above and elsewhere [34, 52],trations (Figure 6E). The data show that the response
of mCAB to FK506 is comparable to that of the FRB* except that the reporter gene encodes a nutritional
marker. By coupling yeast survival to small molecule-domain to rapamycin. To explore the use of multiple
different dimerization domains in a single experiment, dependent protein-protein interaction, we can simulta-
neously query a larger proportion of sequence space.we took advantage of the fact that rapamycin and FK506
both bind the same primary target, namely FKBP12. To implement this strategy, we fused mCAB to a BD
from the bacterial transcription factor LexA [53] (mCAB-Specifically, we cotransfected Jurkat cells with reporter,
bait, and both mCAB-AD and FRB-AD. Under these cir- LexA) and fused FKBP12 to the transcriptional activator
B42 [57] (FKBP-B42). Yeast cells were cotransformedcumstances, either FK506 or rapamycin was able to
stimulate production of AP, and treatment with both with these two constructs and with a reporter gene en-
Chemistry & Biology
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Figure 5. Activity and Inhibition of fCAB Protein
(A) Jurkat cells were transfected with NRE-AP reporter (50 ng/106 cells) and either empty pBJ5X vector or fCAB-HA (400 ng/106 cells), followed
by treatment with PMA, Io, and FK506, as indicated, for 24 hr. Data are plotted as the average and standard deviation from either 24 (Mock 
PMA) or six (Mock  PMA/Io, fCAB  PMA) independent experiments.
(B) Jurkat cells were transfected with NRE-AP reporter (50 ng/106 cells) and the indicated amount (per 106 cells) of fCAB-HA, followed by
treatment with PMA and serial dilutions of FK506 for 24 hr. Data are plotted as the average of duplicate experiments.
(C) Jurkat cells were transfected with NRE-AP reporter (50 ng/106 cells) and the indicated amount (per 106 cells) of fCAB-HA, followed by
treatment with PMA and serial dilutions of C40-Ph (3) for 24 hr. Data are plotted as the average of duplicate experiments.
(D) Jurkat cells were transfected with 0, 100, or 400 ng (per 106 cells) of fCAB-HA. After 24 hr, cleared cell lysates were separated by SDS-
PAGE, transferred to nitrocellulose, and probed with -HA monoclonal antibody.
coding the nutritional markers LEU2 and URA3 under cineurin and to mediate AP production via mCAB-AD.
For this reason, we deemed 4 our best “bump” com-the control of a LexA-inducible promoter.
Our strategy for mutagenesis benefited from the pre- pound and restricted our screen for a compensatory
mutant “hole” in mCAB to 4.vious identification of CnB residues contacting the
FKBP12-FK506 complex [41]. In particular, the third EF Sequence analysis of clones selected by yeast three-
hybrid screening revealed a strong preference by 4 forhand of CnB contains several residues that contact the
terminal olefin (C39-C40) of FK506 (Figure 7B). We pre- the substitution M118G in CnB. This collection of clones
allowed us to determine a consensus sequence,pared a three-position library of mutant mCAB alleles
by randomizing the sequence LKMMV of CnB (residues [L|V]KMG[C|S], for the mutated region (Figure 8A). To
validate these results, we independently prepared sev-116–120) to XKMXX. This library was screened (as a
fusion to LexA) in the yeast three-hybrid system on agar eral mutant alleles of mCAB-AD by site-directed muta-
genesis. These alleles corresponded to CnB mutantscontaining a low concentration (10 nM) of 4 at which
“wild-type” mCAB-AD does not promote growth. We (residues 116–120) LKMGV, LKMGC, LKMGS, VKMGC,
and VKMGS. Each of these constructs was introducedidentified fourteen clones during the primary screen and
retested each at varying concentrations of 1 or 4. In into the mammalian three-hybrid system (as an AD fu-
sion) to test whether any could restore binding to 4. Ofparticular, we identified one clone that restored the pat-
tern of growth to that induced by “wild-type” mCAB-AD these proteins, the mutant mCABVKMGC (L116V/M119G/
V120C; hereafter termed mCAB*) was best suited toin combination with FK506 (Figure 7C). We chose 4 for
yeast screening because of its performance in the cal- restore binding, as judged by the most pronounced left-
ward shift in EC50 (Figure 8B). Interestingly, this proteincineurin inhibition assay and the mammalian three-
hybrid system. Specifically, 4 showed the most impaired had little effect on the dose-response to 3 in the same
assay. Indeed, at modest concentrations of CID (30 nM),ability, relative to 1, both to inhibit endogenous cal-
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Figure 6. Activity of mCAB Protein in Mammalian Cells
(A) Mammalian three-hybrid system used in this study. Schematic representations include CID (red), bait protein (green), effector protein
(blue), and DNA (cyan).
(B) Jurkat cells were transfected with NRE-AP reporter (50 ng/106 cells), BD-F3 bait (150 ng/106 cells), and mCAB-AD (50 ng/106 cells), followed
by treatment with the indicated amount of 1, 3, or 4, for 24 hr. Data are plotted as the average and standard deviation of either 12 [FK506
(1), C40-Ph (3)] or two [C40-PhOPh (4)] independent experiments.
(C) Jurkat cells were transfected as in (B) except that a variable amount (per 106 cells) of mCAB-AD DNA and a fixed concentration (100 nM)
of FK506 were used. After 24 hr, one set of aliquots was lysed for separation by SDS-PAGE, transferred to nitrocellulose, and probed with
-FLAG monoclonal antibody while another identical set was tested for AP activity, which is plotted as the average and standard deviation
of six independent experiments.
(D) Jurkat cells were transfected with mCAB-AD (100 ng/106 cells) and FKBP-HA (400 ng/106 cells) (see Experimental Procedures), followed
by treatment with or without FK506 (200 nM) for 24 hr. -HA immunoprecipitates were separated by SDS-PAGE, transferred to nitrocellulose,
and probed with -FLAG monoclonal antibody. The standard band is a cleared lysate from the 150 ng sample shown in (C).
(E) Jurkat cells were transfected with reporter and bait as in (B) and with either FRB*-AD or mCAB-AD (50 ng/106 cells), followed by treatment
with CsA (1 M), rapamycin (100 nM), or FK506 (200 nM) for 24 hr. AP activity is plotted as the average and standard deviation of six
independent experiments.
(F) Jurkat cells were transfected with reporter and bait as in (B) and with both FRB*-AD and mCAB-AD (each at 50 ng/106 cells), followed by
treatment with rapamycin (100 nM), FK506 (200 nM), or both, for 24 hr. AP activity is plotted as the average and standard deviation of four
independent experiments.
AP production by the combination of 4 with mCAB*-AD Discussion
exceeds that of 1 in combination with mCAB-AD (Figure
Resculpting of the small molecule-protein interface be-8C). To rule out the possiblity that mutant protein levels
were responsible for this effect, we compared expres- tween FK506 and the calcineurin A/B heterodimer took
place in three stages. First, we prepared calcineurin-sion levels for mCAB-AD and mCAB*-AD by Western blot
analysis (Figure 8D), which revealed comparable expres- resistant derivatives of FK506 by using crossed olefin
metathesis to append steric bulk to the C39-C40 termi-sion levels for the two proteins. These experiments confirm
the result of the yeast three-hybrid selection and provide nal olefin of FK506. We used a reporter gene assay to
test the ability of such derivatives to inhibit endogenousnot only a new dimerizer system available for immediate
use, but also a set of guidelines for its use in transfection calcineurin. Next, we prepared calcineurin A/B fusion
proteins, termed CABs, to identify a binding module forexperiments. Future studies of the interaction between
FK506 (or its derivatives) and CAB proteins might shed the FKBP12-FK506 complex. The ability of CAB domains
to bind FKBP12-FK506 was judged with two differentlight on the structural basis for binding in these novel
small molecule-protein complexes. chemical genetic approaches. We used ionomycin (Io)
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Figure 7. Selection of Mutant Proteins by the Yeast Three-Hybrid System
(A) Yeast three-hybrid system used in this study. Schematic representations include CID (red), bait protein (green), effector protein (blue), and
DNA (cyan).
(B) Close-up of the interface between FK506 and CnB. The image is based on the same crystallographic coordinates and follows the same
color scheme as that in Figure 2. The terminal olefin (C39-C40) of FK506 protrudes into a binding pocket formed by several amino acid side
chains. Shown in space-filling representation (yellow) are the side chains of the three residues (CnB; L116, M119, V120) randomized by
degenerate PCR mutagenesis to prepare the yeast three-hybrid library.
(C) After negative and positive selection (see Experimental Procedures), individual yeast clones were replica spotted on His/Trp/Leu-dropout
agar containing the indicated concentration of FK506 or 4 and allowed to grow at 30C for 72 hr before photography of the resulting colonies
(approximately 5	 magnification).
and FK506 to dissect the contributions of fCAB and recruit proteins containing an mCAB* domain without
any effect on endogenous calcineurin. This relationshipendogenous calcineurin in an FK506-sensitive reporter
gene assay. These experiments were made possible by is analogous to the therapeutic index relating the effi-
cacy and toxicity of a drug. The mCAB* domain, usedthe omission of the autoinhibitory domain (AID) of CnA
[41, 49, 50] from the fCAB fusion protein, which renders in tandem with C40-p-phenoxyphenyl-FK506, provides
an opportunity to elicit a dose response in cell culturethis protein a calcium-independent source of calcineurin
phosphatase activity. Thus, experiments conducted in without interfering with endogenous signaling path-
ways. Because C40-p-phenoxyphenyl-FK506 is unablethe presence and absence of Io could be used to distin-
guish fCAB activity from endogenous calcineurin activ- to inhibit endogenous calcineurin, as judged by the use
of an NFAT-responsive reporter, its use should beity. Additionally, we used FK506 and derivatives as
chemical activators of transcription in both yeast and broadly applicable to dimerizer systems that use mCAB*
as one of the dimerization domains. This property of themammalian three-hybrid systems. These experiments
were inspired by the natural dimerizer property of FK506 mCAB* system improves the chance that a particular
signaling process can be studied in a dimerizer system.[58], which allowed us rapidly to test mCAB constructs
for docking activity (measured by recruitment of AD) in One compelling potential feature of CABs as dimeriza-
tion domains remains to be explored. Calcineurin is alsoa cellular context.
In the mammalian three-hybrid system, we were able the target of the cyclophilin-CsA complex [35]. Although
the interaction of fCAB or mCAB with this complex re-to control the interaction of three interacting molecules
either by varying the dose of dimerizer or by changing mains to be tested, it is possible that some incarnation
of a CAB protein could be engineered (or selected) tothe concentration of transfected DNA encoding the
mCAB-AD fusion protein. Specifically, increasing the dock not only with FKBP12-FK506 but also with cyclophi-
lin-CsA. Should this prove to be true, the CAB domainamount of mCAB*-AD results in an increased sensitivity
of the system to C40-p-phenoxyphenyl-FK506 (P.A.C. could assume broader roles in multicomponent dimer-
ization systems because of its ability to dock with twoand S.L.S., unpublished data). This fact has an important
implication for the use of C40-p-phenoxyphenyl-FK506 different partners under the control of two different small
molecules. If a CAB domain were prepared that couldand mCAB*-AD as a calcineurin-resistant dimerizer sys-
tem. Because endogenous levels of calcineurin are rela- bind both complexes, one could imagine engineering
cells or animals in which a fusion of CAB to some effectortively low, our results predict a broad dose window in
which C40-p-phenoxyphenyl-FK506 could be used to domain was present in the same cell as two other fusion
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Figure 8. Validation of Selected Hits for C40-p-Phenoxyphenyl-FK506 (4) in Mammalian Cells
(A) Sequence of representative hits and consensus sequence for compensatory proteins.
(B) Jurkat cells were transfected with NRE-AP reporter (50 ng/106 cells), BD-F3 bait (150 ng/106 cells), and either mCAB-AD or mCAB*-AD
(50 ng/106 cells), followed by treatment with the indicated amount of 1, 3, or 4, for 24 hr. Data are plotted as the average of at least 4
independent experiments, and error bars (where present) indicate the standard deviation of the mean.
(C) Jurkat cells were transfected as in (B), then treated with either 1 or 4 (30 nM) for 48 hr. AP activity is plotted as the average and standard
deviation of two independent experiments.
(D) Jurkat cells were transfected as in (B), except that a variable amount (per 106 cells) of mCAB-AD or mCAB*-AD DNA was used, as indicated.
After 24 hr, cleared cell lysates were separated by SDS-PAGE, transferred to nitrocellulose, and probed with -HA monoclonal antibody.
proteins, one containing FKBP12 and one containing allow the ordered assembly of complexes containing
more than two fusion proteins of interest.cyclophilin. In this scenario, the addition of FK506 or CsA
would result in the formation of alternative complexes
between mCAB and another dimerization domain. The Significance
use of tandem modular domains in this context would
further enable the assembly of specific multicomponent We have used chemical genetic selection to discover
a novel small molecule-protein combination based oncomplexes under the control of multiple dimerizers.
Finally, the advent of CAB domains themselves allows the inhibitory complex between FKBP12-FK506 and
the protein phosphatase calcineurin. This study usedsuch multicomponent dimerization experiments. Both
rapamycin and FK506 can now be used to recruit differ- a combination of synthetic chemistry, molecular biol-
ogy, fusion protein engineering, and a phenotypic, cell-ent modules (FRB and CAB, respectively) to fusion pro-
teins containing FKBP12. As described above and else- based assay to modify components of an existing
small molecule-protein complex. By combining thesewhere [1, 36, 37], both homo- and heterodimerizers have
been used to exercise control over protein association techniques, we were able to synthesize small mole-
cules and screen them directly in a context that re-under circumstances in which at most two different engi-
neered proteins are specifically being induced to associ- quires both solubility and cell permeability, rather than
having to test for these properties in separate experi-ate. Signal transduction in general, however, is charac-
terized by the orderly formation of complex collections ments. Guided by previous crystallographic work, we
were able to select sites for both derivatization (of theof proteins [59]. Docking domains based on novel small
molecule-protein interactions extend the power of di- small molecule) and mutagenesis (of the protein). Our
use of a phenotypic assay, in this case the yeast three-merizer methods to include multicomponent associa-
tions. For such studies, it is clearly desirable to have hybrid assay, allowed the simultaneous query of a
large proportion of sequence space for our mutantmultiple small molecule-protein combinations that not
only protect endogenous signaling molecules (e.g., proteins and enabled the rapid identification of a novel
receptor.FRAP and calcineurin) from inhibitory effects but also
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Experimental Procedures the reaction itself, which is difficult to determine exactly because
of the loss of both FK506 and C40 adducts in shaved HPLC peaks.
One additional four-cycle purification step (using the sizing columns)Extraction of FK506 from Prograf Capsules
Prescription FK506 was purchased from CVS Pharmacy as Prograf was required to remove all traces of FK506 (as judged by FAB-
MS) and ruthenium contaminants (as judged by brown color). Thecapsules containing 5 mg FK506 each as a pharmaceutical prepara-
tion (Fujisawa). Capsules were opened manually, and bulk powder resulting single HPLC peaks corresponding to both 3 and 4 were
analyzed by 1 H-NMR, and each was assigned (E) double-bond ge-was crushed with a mortar and pestle before resuspension in 300
L H2O per mg of active ingredient. FK506 (1) was extracted by ometry at C39-C40. We cannot precisely comment on the stereose-
lectivity of this reaction because the (Z) product may simply havethe addition of 700 L ethyl acetate (EA) per mg to the aqueous
suspension, which was then transferred to a separatory funnel. The separated poorly from FK506 and may have entered shaved peak
fractions regardless of its relative abundance. In all, 3 and 4 wereinitial EA fraction was set aside and pooled with three additional
EA extracts of the aqueous suspension. The pooled EA fractions each subjected to three purification steps, totaling fourteen HPLC
injection cycles, on two different instruments. Though the yield forwere back-extracted with an equal volume of H2O until very little
particulate matter was visible in the organic phase (at least three these reactions is poor overall, the isolated products are completely
free of FK506, which is essential for testing their activity in a cellulartimes). The organic phase was passed through Celite and a plug of
glass wool, then dried over magnesium sulfate (MgSO4). Purified context.
FK506 was collected from the EA fraction by rotary evaporation,
with recovery of 96% of the material (4.8 mg/capsule). The identity DNA Constructs and PCR Mutagenesis
of 1 was confirmed at this stage by FAB-MS and 1 H-NMR. The constructs NRE-AP, GRE-AP, and BD-F3 have been described
previously [4, 45, 46]. FRB*-AD was prepared (B.N. Desai, P. T.-X.
Ngheim, P.A.C., and S.L.S., unpublished data) by PCR amplificationSynthesis of C40 Derivatives of FK506
C40 derivatives of FK506 were prepared by a modification of the of FRB* with a construct described by Liberles et al. as a template
[34]; the encoded domain consists of mutant FRAP sequence corre-procedure reported by Diver and Schreiber for the synthesis of
FK1012 by olefin metathesis [11]. FK506 (1) was added in dichloro- sponding to amino acid residues 2025–2114 in the full-length protein
[32, 34, 52]. All new constructs for mammalian expression weremethane (CH2Cl2) to an oven-dried 10 ml round-bottom flask
equipped with a magnetic stir bar and rubber septum. Neat styrene prepared with pBJ5X (P.A.C. and S.L.S., unpublished results), a
pBJ5 derivative [60] that places an open reading frame (ORF) up-or substituted styrene was added by pipettor; care was taken to
pre-coat the pipet tip to ensure accurate volumetric transfer of the stream of an in-frame hemagglutinnin (HA) epitope tag [61] and
downstream of a strong (SR) mammalian promoter [60]. The pBJ5Xliquid reagent. In each reaction, 15 equivalents of styrene or substi-
tuted styrene was added, after which the septum was sealed and plasmid contains a custom polylinker sequence (GCGGCCGCGGCC
ACCATGCTCGAG-ORF-GTCGAC-HA-ACTAGTTAATATAATAGAAthe vessel purged with Ar. Grubbs’ catalyst (2; bis-(tricyclohexyl-
phosphine)-ruthenium(IV) benzylidne dichloride) was obtained com- TTC) that allows for modular preparation of fusion proteins. Each
of the XhoI, SalI, and SpeI restriction sites consists of six nucleotidesmercially (Strem) and stored under Ar after each use. Reaction mix-
tures were supplemented with 0.2 equivalents of 2 in a small portion in frame with the ORF encoding the inserted domain. Furthermore,
because XhoI and SalI digests result in complementary overhangs,of dry CH2Cl2 so that the final concentration of reagents was 10 mM
FK506, 150 mM styrene or substituted styrene, and 2 mM catalyst. inserts excised from pBJ5X can be ligated directionally into an ap-
propriately digested pBJ5X acceptor plasmid to generate con-Reactions were allowed to proceed at reflux temperature (40C) with
stirring for 24 hr, at which time a second portion of 2 was added structs encoding either N- or C-terminal fusion proteins. In particu-
lar, constructs encoding the desired fragments of calcineurin werefor an additional 24 hr. White precipitate (stilbene or substituted
stilbene) was removed by passing crude reactions through Celite prepared by PCR amplification of nucleotide sequences corre-
sponding to (1) residues 12–394 of human CnA, (2) residues 340–394and glass wool. Extraction with EA, drying with MgSO4, and rotary
evaporation produced dark brown oils containing FK506, C40-sub- of human CnA, and (3) residues 3–170 of human CnB, then direc-
tional ligation into pBJ5X. fCAB was prepared by ligating the CnBstituted FK506, and FK1012, as judged by the presence of parent
ion peaks in FAB-MS experiments. These mixtures were further sequence downstream of the long CnA sequence (encoding CnA
12–394), and mCAB was prepared by ligating the CnB sequencepurified by normal-phase HPLC in CHCl3 as described below.
downstream of the short CnA sequence (encoding CnA 340–394).
Fusion proteins to the AD of human p65 (residues 361–551) werePurification of C40 Derivatives of FK506
prepared by PCR amplification of an XhoI-EcoRI fragment of p65,Purification of C40 derivatives of FK506 was essential to the success
which was ligated directionally into similarly digested CAB con-of this study. Fortunately, our efforts at removing all traces of FK506
structs, resulting in loss of the HA tag (see below). Site-directedfrom reaction mixtures were aided by the fact that FK506 and its
mutant CAB constructs were prepared by overlap extension PCRderivatives ionize very well by FAB-MS. We confirmed by spike-
of CnB, with oligonucleotides encoding mutant protein sequencein experiments that as little as 0.05% contamination by FK506 is
used as internal primers. Internal primer sequences at mutant co-detectable as an MNa parent ion peak by this sensitive measure-
dons was chosen based on mammalian codon preferences [62].ment. Thus, we analyzed the HPLC fractions described below by
These mutant CnB fragments were subsequently used to generateFAB-MS and continued purification until no M  Na peak corre-
fCAB or mCAB constructs exactly as described above. Constructsponding to FK506 was present in the spectrum. This allowed small
identity was generally determined by restriction mapping and wasquantities of HPLC eluate to be analyzed quickly and obviated the
subsequently confirmed for any segment introduced by PCR usingneed to exchange the entire fraction into deuterated solvent be-
DNA seqencing. All DNA destined for transfection into mammaliantween each purification step. Furthermore, this method ensures
cells was further purified by phenol-CHCl3 extraction and ethanolgreater than 99.95% purity of the final products, which is far better
precipitation following purification from bacterial cells by the usethan that obtained by conventional chromatography (monitored by
of commercially available reagents (Promega).TLC and NMR). We first chromatographed filtered reaction mixtures
on an HPLC instrument bearing two tandem sizing columns (Japan
Analytical Industries). After four cycles of injection, no trace of Transfections, Immunoblots, and Immunoprecipitation
For experiments involving mammalian cells, mCAB-p65 was excisedFK1012 was observed by FAB-MS in a mixture still containing both
FK506 and C40 derivatives, which are relatively similar in mass. To from pBJ5X (see above) and inserted into pBJ5E [32–34], which
contains a similar polylinker (ATG-FLAG-GCGGCCGCGCTCGAG-separate FK506 from C40 derivatives, we used a recycling HPLC
instrument bearing two tandem affinity columns (Japan Analytical ORF-GTCGACTAATATAATAGAATTC) encoding an N-terminal FLAG
epitope tag instead of a C-terminal HA tag. All cell culture experi-Industries). After six to eight injection cycles with peak-shaving, we
isolated the C40-phenyl (3) and C40-p-phenoxyphenyl (4) adducts, ments were performed with “TAg” Jurkat cells, a human Jurkat T cell
lymphoma line derivative that is stably transfected with SV40 largeeach in approximately 20% recovery. Furthermore, approximately
50% of the original mass of FK506 was recovered in both cases. T antigen [63]. Cells were cultivated in RPMI-1640 medium (Gibco
BRL) supplemented with 10% (v/v) fetal bovine serum, 2 mMThese observations provide upper and lower limits for the yield of
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L-glutamine, 100 units/ml penicillin, and 1 mg/ml streptomycin and for plasmid DNA encoding the p65 subunit of human NF-B. The
yeast strain YL(6.4)LU was graciously provided by Dr. Jing Huang.were grown at 37C and 5% CO2 in a humidified incubator. Prior to
transfection, cells were grown to a density of 106 /ml and incubated S.L.S. is an Investigator with the Howard Hughes Medical Institute
at the Department of Chemistry and Chemical Biology, Harvardwith DNA for 10 min before electroporation with an ElectroCell Ma-
nipulator (BTX) at 250 V. Pulse lengths were controlled to 39–42 ms University.
by using identically treated samples to optimize the capacitance
(960–1040 F). Cells were allowed to incubate for 10 min after elec- Received: August 7, 2001
troporation before resuspension in cell culture media at 106 cells/ Accepted: October 2, 2001
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